DarshanTalks Podcast
Welcome to DarshanTalks!
We demystify fraud for legal, regulatory, and compliance essentials in the life sciences and pharmacy industries. Through engaging 15-30-minute interviews with influential change makers, short educational regulatory defbriefs, and 60 second audio takeaways, we unveil the strategies behind bringing drugs and devices to market—and keeping them there!
Powered By The Kulkarni Law Firm - Helping regulators see your business the way you do.
We focus on life science issues involving medical affairs, marketing and advertising, and clinical research so that you can learn about the industry, enhance your business and grow your career.
DarshanTalks Podcast
Final LGBTQ Individuals in clinical research
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
Today we're gonna talk about clinical trial sponsors and about a critical segment in the population. LGBTQ community. Now, I know the current climate, but the change in the administration, the FTA's diversity action plans, the DAPs, have been deprioritized. Certain LGBTQ requirements were even withdrawn. I might be tempted to think this is the problem for later. Here's the reality. LGBTQ individuals are your end users, but Gen Z identifying as much as 20% as LGBTQ, ignoring this community means you're essentially excluding yourself from one-fifth of your future markets. At the Cole County Law Firm, we help you think five to ten years ahead. Fact is that career scientists at the FDA, the deep state, if you will, they aren't going anywhere. If you submit a study years from now that lacks representative data, you risk massive costs and unavoidable delays. Why move your own finish line when you can plan for this upfront and you can actually be proactive about this? Furthermore, when a drug approval hangs by a thread, you want most organized advocates in your corner. LGBTQ communities are actually exceptionally well at being organized. This can be the difference between a yes and a no from the FDA.
SPEAKER_00Enjoying our content, we'd love to hear more. Please like, comment, share, and find more.
DarshanThis is about better science. If you aren't asked the right questions about hormones or biology, you're missing critical safety data. Like the increased risk of blood clots. For patients on estrogen, for example, inclusion also drives retention. If your clinical study site doesn't know how to respectfully engage, if they use the wrong pronouns, if they make exclusionary assumptions, your participants leave. And with that, your customers leave. That is lost data and a fail strategy. Pause in federal mandates is actually your opportunity to restrategize to build a bigger funnel. At the Kilkarney Law Firm, we focus on FDA regulatory law and compliance, and we ensure that your research is both scientifically rigorous and future-proof. Don't just meet the minimum, lead the field. If you found this insight to be valuable, please subscribe to Darchan Talk for more deep dives. For legal guidance on your clinical trial strategy, visit us at KilkarnelawFirm.com. Thanks for listening. Call, click, or email.
